5MG
Ships Tomorrow morning if ordered within 14 hrs 28 min.
Buy 3+ for $41.80 each and save 5%
Buy 5+ for $39.60 each and save 10%
Buy 10+ for $37.40 each and save 15%
This product is for research purposes only. Not for human consumption.
Purity: >98% (HPLC verified)
Formulation: Lyophilized powder
Molecular Formula: C33H57N11O9
Molecular Weight: 751.9 g/mol
CAS Number: 129954-34-3
PubChem CID: 11765600
Research Contents
Selank
Overview
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro that was developed in Russia through collaborative research between the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology. The peptide is based on the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), which is derived from the Fc fragment of immunoglobulin G and plays roles in immune system activation and phagocytosis.
Enhanced Stability Through Rational Design
Selank represents an engineered extension of tuftsin with three additional proline residues (Pro-Gly-Pro) at the C-terminus—modifications that dramatically enhance metabolic stability, extend the half-life from minutes to hours, improve blood-brain barrier penetration, and amplify bioactivity compared to native tuftsin. This rational design approach has created a peptide with remarkable anxiolytic (anti-anxiety), nootropic (cognitive-enhancing), antidepressant, antiasthenic (anti-fatigue), and immunomodulatory properties that distinguish it from conventional psychiatric medications.
A Safer Alternative to Benzodiazepines
Selank was specifically developed as a safer alternative to benzodiazepines for treating anxiety disorders. While benzodiazepines are highly effective anxiolytics, they cause sedation, cognitive impairment, psychomotor slowing, tolerance, physical dependence, and withdrawal syndromes that limit their utility, particularly for long-term use. Selank produces significant anxiolytic effects without sedation, cognitive impairment, or dependence liability, representing a fundamentally different approach to anxiety treatment.
Clinical Development and Approval
The peptide has undergone extensive preclinical research and clinical trials in Russia, leading to regulatory approval for clinical use in Russia and several other former Soviet countries for treatment of generalized anxiety disorder and neurasthenia. Beyond anxiety, research has revealed nootropic properties including improvements in memory, learning, attention, and mental clarity, as well as adaptogenic effects supporting stress resilience and performance under demanding conditions.
Multifaceted Mechanism
Selank's mechanism involves complex modulation of neurotransmitter systems, neurotrophic factors, and immune function rather than simple receptor agonism or antagonism, contributing to its multifaceted effects and favorable side effect profile. The peptide is typically administered via intranasal drops, which provides good bioavailability and convenient use. Research interest in Selank extends beyond Russia, with international studies exploring its potential applications in various neuropsychiatric conditions.
Mechanism of Action
Selank exerts its diverse neuropsychiatric effects through multiple interconnected mechanisms affecting neurotransmitter systems, neurotrophic factors, gene expression, and immune function. Unlike benzodiazepines (which directly potentiate GABAergic inhibitory neurotransmission through GABA-A receptor allosteric modulation) or selective serotonin reuptake inhibitors (which increase serotonergic signaling), Selank works through more subtle and multifaceted modulation of neural function.
Monoamine Neurotransmitter Modulation
Selank influences the metabolism and levels of monoamines including serotonin, dopamine, and norepinephrine in key brain regions. Research has shown that Selank administration normalizes altered levels of these neurotransmitters in stress and anxiety states—increasing deficient levels and moderating excessive levels in a homeostatic regulatory pattern rather than simple stimulation or inhibition. The peptide affects the expression and activity of enzymes involved in neurotransmitter metabolism, including monoamine oxidase (MAO), helping optimize monoaminergic neurotransmission crucial for mood, anxiety, cognition, and motivation.
GABAergic System Effects
Selank influences the GABAergic system, the primary inhibitory neurotransmitter system in the brain and a key target for anxiolytic drugs. However, unlike benzodiazepines that directly bind GABA-A receptors, Selank modulates GABAergic function through indirect mechanisms including effects on GABA metabolism, transporter expression, and neural circuit function. This indirect modulation produces anxiolytic effects without the sedation, motor impairment, and dependence associated with direct GABA-A receptor agonists.
BDNF and Neuroplasticity
A particularly important aspect of Selank's mechanism involves brain-derived neurotrophic factor (BDNF), a critical neurotrophin that supports neuronal survival, growth, differentiation, and synaptic plasticity. Selank has been shown to upregulate BDNF expression in the hippocampus and other brain regions, supporting neuroplasticity—the brain's ability to form new neural connections, adapt to experiences, and recover from stress or injury. BDNF enhancement is increasingly recognized as an important mechanism for antidepressant and cognitive-enhancing effects.
Immunomodulatory and HPA Axis Effects
Like its parent peptide tuftsin, Selank exhibits immunomodulatory properties, influencing cytokine production, immune cell function, and inflammatory responses. Research shows Selank can normalize dysregulated cytokine patterns and reduce excessive inflammatory responses. The peptide also influences the hypothalamic-pituitary-adrenal (HPA) axis, normalizing stress-induced activation and supporting healthier stress responses without completely suppressing the system's necessary functions.
Research Findings
Research on Selank encompasses over two decades of preclinical studies in rodent models and clinical trials primarily conducted in Russia, with growing international interest in recent years.
Preclinical Anxiolytic Studies
Early preclinical studies characterized Selank's anxiolytic properties using standard anxiety models including the elevated plus maze, open field test, and conflict tests. These studies consistently demonstrated that Selank produces anxiolytic effects comparable in magnitude to benzodiazepines like diazepam but without the sedation, motor impairment, or habituation. Importantly, animals receiving Selank maintained normal exploratory behavior and learning ability while showing reduced anxiety-like behaviors.
Stress Resilience and Cognitive Enhancement
Stress resilience studies showed that Selank pretreatment could protect against various stressors including restraint stress, cold stress, and psychological stress, with animals showing better maintenance of normal behaviors and faster recovery. Memory and learning research demonstrated that Selank enhances performance in various cognitive tasks including spatial memory tests (Morris water maze), object recognition tests, and passive avoidance learning. The cognitive enhancement occurred in both normal animals and those with experimentally induced memory impairments.
Clinical Trial Results
Clinical trials in patients with generalized anxiety disorder and neurasthenia have shown significant therapeutic benefits. Studies published in Russian psychiatric journals reported that Selank treatment (typically 2-3 drops per nostril 2-3 times daily for 2-4 weeks) produced significant reductions in anxiety symptoms, with efficacy comparable to standard anxiolytic medications but with superior tolerability profiles. Patients reported reduced anxiety, improved mood, better stress tolerance, enhanced mental clarity and focus, and improved overall well-being—without the sedation, cognitive dulling, or psychomotor slowing typical of benzodiazepines.
Lasting Benefits and Safety Data
Follow-up studies showed that therapeutic benefits could persist for weeks after discontinuation, suggesting disease-modifying or adaptive effects rather than simple symptom suppression. Safety and tolerability data from clinical trials has been excellent, with no serious adverse events reported. Comparative studies with benzodiazepines have highlighted Selank's advantages including lack of sedation, preservation of cognitive function, absence of tolerance or dependence, and no withdrawal symptoms upon discontinuation.
Research Applications
- Generalized anxiety disorder and anxiety research
- Stress resilience and adaptogenic effects research
- Cognitive enhancement and nootropic studies
- Depression and mood disorder research
- BDNF modulation and neuroplasticity studies
- Neurotransmitter system regulation research
- Mental fatigue and asthenia treatment studies
- Immune system modulation research
- HPA axis and stress response regulation
- Memory and learning enhancement research
- Attention and focus improvement studies
- Combination therapy with standard psychiatric medications
Safety Profile
Selank has demonstrated an exceptional safety profile across extensive preclinical studies and clinical trials, distinguishing it from conventional anxiolytic and psychiatric medications that often carry significant side effect burdens.
Minimal Adverse Effects
Clinical trials involving thousands of patients in Russia over two decades have reported minimal adverse effects, with the most common being occasional mild nasal irritation from the intranasal administration route—a localized, transient effect unrelated to systemic peptide activity.
No Benzodiazepine-Like Problems
Importantly, Selank does not produce the problematic effects associated with benzodiazepines: no sedation or drowsiness allowing normal daily activities, no cognitive impairment or memory problems, no psychomotor slowing or coordination issues, no tolerance development requiring dose escalation, no physical dependence or addiction potential, and no withdrawal syndrome upon discontinuation. This safety advantage is particularly significant for long-term treatment and for patients who need to maintain cognitive function for work or study.
Excellent Safety Margins
Overdose appears to have minimal consequences, with animal studies showing very high LD50 values that are many hundreds of times higher than therapeutic doses. Selank does not interact significantly with alcohol or most other medications. The peptide does not affect blood pressure, heart rate, or other vital signs at therapeutic doses. Liver and kidney function tests in clinical trials have shown no adverse effects.
Long-Term Safety Profile
Long-term use over months to years in clinical practice has not revealed cumulative toxicity or late-onset adverse effects. The approved status in Russia and clinical use experience provides real-world safety validation beyond controlled trials. Compared to SSRIs (which can cause sexual dysfunction, weight gain, and withdrawal difficulties), SNRIs, tricyclic antidepressants, and other psychiatric medications, Selank's side effect profile is remarkably clean.
Scientific References
Customer Reviews
No reviews yet. Be the first to review this product!
Please sign in to write a review.
Research Use Only
This product is intended for research purposes only and is not for human consumption, therapeutic use, or diagnostic applications. Please ensure compliance with all applicable regulations and institutional guidelines.